ASND · Ascendis Pharma A/S · Metrics
$271.19
-0.54 (-0.20%)
At close · Nov 17
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$17.79B
Shares
65.60M
Volume · Nov 17
586.93K
Avg daily vol (3M)
735.38K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
ASND metrics
75 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$271.19
Market cap
$17.79B
Price action
23 metricsPrice change (1W)
+5.7%
Price change (30D)
+17.9%
Price change (3M)
+9.0%
Price change (6M)
+14.0%
Price change (YTD)
+27.2%
Price change (1Y)
+25.2%
Trailing year
Price change (5Y)
+75.0%
52-week high
$277.18
52-week low
$196.63
Change from 52-week high
-2.2%
Change from 52-week low
+37.9%
Annualized volatility
38.1%
Annualized volatility (3M)
36.6%
Implied volatility (30D)
45.3%
IV rank (1Y)
29.9
IV percentile (1Y)
48.5
Beta
0.4
RSI (14D)
69.0
Price vs SMA 50
+11.7%
Price vs SMA 200
+12.8%
Avg volume (3M)
735,354
Relative volume
0.8
Average dollar volume
$180.02M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
65.60M
Valuation
12 metricsP / E (TTM)
17.5
Trailing earnings · reciprocal yield 5.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
12.7×
reciprocal yield 7.9%
P / book
10.5
reciprocal yield 9.6%
FCF yield
—
TTM · current market cap
Buyback yield
1.0%
P / FCF
—
P / operating cash flow
28.6
reciprocal yield 3.5%
Earnings yield
—
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-11-12
Profitability
9 metricsGross margin
91.9%
Operating margin
31.6%
Trailing 12 months
Net margin
72.9%
Gross profit (TTM)
$1.11B
Operating profit (TTM)
$379.75M
Net income (TTM)
$1.02B
Trailing 12 months
Diluted EPS (TTM)
$15.52
FCF margin
—
Effective tax rate
-226.4%
Growth
11 metricsRevenue growth YoY
+73.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.40B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.1%
Year over year · more shares
Revenue CAGR (3Y)
+141.4%
Revenue CAGR (5Y)
+153.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
58.4%
Return on assets
36.1%
Debt / equity
—
Current ratio
2.9
EBITDA (TTM)
$462.44M
Free cash flow (TTM)
—
Quick ratio
2.3
Interest coverage
2.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.09B
Total assets
$2.75B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$621.28M
Capital expenditures (TTM)
—
R&D (TTM)
$328.79M
SG&A (TTM)
—
Stock compensation (TTM)
$140.67M
R&D / revenue
23.5%
Stock compensation / revenue
10.1%
Ownership (13F)
9 metrics13F filers
346
13F filer change QoQ
+31
Institutional ownership
104.1%
Conviction holders (share of 13F filers)
4.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+1.7%
Holder tenure
19.3
Price vs estimated holder cost
+30.8%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.4%
Short interest
3 metricsShort interest
4.6%
Latest settlement · 5.0 days to cover
Days to cover
5.0d
Short-squeeze score
64 / 100
Insider activity
2 metricsNet insider buying (90D)
−$872,905
Insider-sentiment score
32 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1612042
CUSIP
K08588103
13F (30d)
363 filings
333 filers
Visit website
Investor relations